PRTA Prothena Corporation plc
Prothena Corporation plc (PRTA) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.38 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.8% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Prothena Corporation plc
Prothena Corp PLC is a biotechnology company. It discovers and develops novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion.
Sector
Healthcare
Industry
Biotechnology